Allogene Therapeutics Inc (ALLO)
EBITDA Margin
-855.37%
Quarterly · Period ending:
ALLO EBITDA Margin
Latest reported-855.37%period ending
Latest reported-855.37%period ending
ALLO Quarterly EBITDA Margin (0.00% → -855.37%)
Quarterly ebitda margin
High-resolution chart · PNG
ALLO ebitda margin history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| -855.3664% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| -279,295.4545% | |
| 155,572.7273% | |
| -266,886.3636% | |
| -343,586.3636% | |
| -321,536.6667% | |
| -195,274.4681% | |
| -161,812.2449% | |
| -82,688.3721% | |
| -124,849.1803% | |
| -138,482.3529% | |
| -154,808.1633% | |
| -156,754.5455% | |
| -81.583% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |